https://scholars.lib.ntu.edu.tw/handle/123456789/495085
標題: | Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations | 作者: | CHIA-CHI LIN CHIH-HSIN YANG |
公開日期: | 2011 | 卷: | 71 | 期: | 1 | 起(迄)頁: | 79-88 | 來源出版物: | Drugs | 摘要: | In recent years, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, which have promising activity and a favourable toxicity profile, have been used in the management of advanced non-small cell lung cancer (NSCLC). The knowledge that EGFRactivating mutations confer sensitivity to EGFR TKIs has led to the design and analysis of phase II and III studies of gefitinib or erlotinib treatment in various clinical scenarios. We review the important NSCLC clinical trials of the efficacy of EGFR TKIs in the context of EGFR-activating mutations. In all phase II single-arm studies or phase III randomized comparative studies, EGFR TKIs as monotherapy were superior to combination chemotherapy in terms of response rate and progression-free survival in patients with activating EGFR mutations. EGFR TKIs have contributed to the superior overall survival time in NSCLC patients with EGFR mutations compared with those patients without EGFR mutations. The results of these studies have led to a paradigm shift in the treatment of patients with advanced NSCLC. NSCLC with EGFR mutations constitutes a new entity requiring different personalized treatment strategies. ? 2011 Adis Data Information BV. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650851231&doi=10.2165%2f11587560-000000000-00000&partnerID=40&md5=8fa270f2a0934db6da478671163b84d6 https://scholars.lib.ntu.edu.tw/handle/123456789/495085 |
ISSN: | 0012-6667 | DOI: | 10.2165/11587560-000000000-00000 | SDG/關鍵字: | carboplatin; cisplatin; docetaxel; epidermal growth factor receptor; erlotinib; gefitinib; gemcitabine; paclitaxel; placebo; cancer combination chemotherapy; clinical trial; diarrhea; drug efficacy; drug intermittent therapy; gene mutation; human; lung non small cell cancer; monotherapy; outcome assessment; overall survival; progression free survival; quality of life; rash; review; survival time; treatment indication; treatment response; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, Epidermal Growth Factor |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。